Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma
Authors:
- Yann CormeraisYCYann Cormerais
- Marina Pagnuzzi-BoncompagniMPMarina Pagnuzzi-Boncompagni
- Sandra SchrötterSSSandra Schrötter
- Sandy GiulianoSGSandy Giuliano
- Eric TambuttéETEric Tambutté
- Hitoshi EndouHEHitoshi Endou
- Michael F. WempeMWMichael F. Wempe
- Gilles PagèsGPGilles Pagès
- Jacques PouysségurJPJacques Pouysségur
- Vincent PiccoVPVincent Picco
Preprint
Abstract
Most cases of medulloblastoma (MB) occur in young children. While the overall survival rate can be relatively high, current treatments combining surgery, chemo- and radiotherapy are very destructive for patient development and quality of life. Moreover, aggressive forms and recurrences of MB cannot be controlled by classical therapies. Therefore, new therapeutic approaches yielding good efficacy and low toxicity for healthy tissues are required to improve patient outcome. Cancer cells sustain their proliferation by optimizing their nutrient uptake capacities. The L-type amino acid transporter 1 (LAT1) is an essential amino acid carrier overexpressed in aggressive human cancers that was described as a potential therapeutic target. In this study, we investigated the therapeutic potential of JPH203, a LAT1-specific pharmacological inhibitor, on two independent MB cell lines belonging to subgroups 3 (HD-MB03) and Shh (DAOY). We show that while displaying low toxicity towards normal cerebral cells, JPH203 disrupts AA homeostasis, mTORC1 activity, proliferation and survival in MB cells. Moreover, we demonstrate that a long-term treatment with JPH203 does not lead to resistance in MB cells. Therefore, the present study suggests that targeting LAT1 with JPH203 is a promising therapeutic approach for MB treatment.Keywords
All Related Versions
- Published version: Journal of Cellular and Molecular Medicine, 23 (4), 2711.
This publication has 37 references indexed in Scilit:
- NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in MedulloblastomaCancer Cell, 2018
- Challenges and Recent Advances in Medulloblastoma TherapyTrends in Pharmacological Sciences, 2017
- The whole-genome landscape of medulloblastoma subtypesNature, 2017
- Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort studyThe Lancet Oncology, 2017
- Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell, 2017
- The evolution of medulloblastoma therapy to personalized medicineF1000Research, 2017
- Intellectual Outcome in Molecular Subgroups of MedulloblastomaJournal of Clinical Oncology, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Divergent clonal selection dominates medulloblastoma at recurrenceNature, 2016
- Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average‐risk medulloblastoma: COG A9961Pediatric Blood & Cancer, 2013